Innovations
image_only
text_background
Bulb Banner
text_background

Pachymatrix Innovative Keratoconus Therapy

Categories for this invention

Opthalmology

Regenerative Medicine

 

Intellectual Property

OPHTHALMIC COMPOSITIONS AND METHODS OF USE THEREFOR

PCT

WO/2016/140581
 

Image Gallery

 

CSFR1 Binding_0.png

Questions about this Technology?

Contact: Sandhya Badrinarayanan

 

Summary

Researchers from the University of Auckland Department of Ophthalmology have developed a topical eye formula to treat and reverse the symptoms of Keratoconus without the need for invasive ocular surgery. Preclinical ex-vivo large animal studies have shown efficacy of the formulation in reprogramming stromal keratocyes to deposit new non-scarring collagen. This technology may have applicability for any ocular disorder involving thinning or misshaping of the cornea such as myopia.

 

Problems Addressed

Keratoconus is a degenerative eye disease characterized by the progressive thinning and scarring of the cornea. A feature of Keratoconus is the development of a conically shaped cornea, this is commonly associated with symptoms including blurry vision, double vision, astigmatism and light sensitivity.

 

Applications

As a non-invasive treatment method, Pachymatrix bypasses many of the patient risks related with surgical procedures. The technology is applicable to all stages of keratoconus, thereby replacing all other treatments. Studies indicate Pachymatrix may also be relevant in the treatment of Myopia (Short-sightedness).

 

Technology

Pachymatrix halts disease progression and repairs the diseased cornea to restore vision. Pachymatrix uses a patented formulation of a growth factor and steroid administered as simple eye-drops. The formulation has been shown to help lay down transparent Type-II Collagen and remove scarring of the cornea.

 

Advantages

  • Non-invasive procedure
  • Eye-drops are easy to administer
  • Halts disease progression and Restores Visual Function
  • Applicable to all stages of disease progression
  • IP & Patent Ownership Confirmed
  • Also be Applicable in Myopia

 

PROJECT#33240

Inventors

Professor Colin Green

Connexin Biology Group

Department of Opthalmology

 

Professor Trevor Sherwin

Cornea and Stem Cells Group

Department of Opthalmology

 

Dr Carol Ann Greene

Department of Opthalmology

Faculty of Medical and Health Sciences